**RT-HaND\_C Retrospective Dataset Build SOP Appendix 4: Dataset Features**

Last updated: 12/11/2024

Examples of tables demonstrating patient population of dataset.

|  |  |  |
| --- | --- | --- |
| **Gender** | **n** | **%** |
| Female | 805 | 27.8% |
| Male | 2090 | 72.2% |

|  |  |  |
| --- | --- | --- |
| **Race Group** | **n** | **%** |
| Asian Groups | 97 | 3.4% |
| Black Groups | 180 | 6.2% |
| White Groups | 1998 | 69.0% |
| Other Groups | 110 | 3.8% |
| Unknown | 510 | 17.6% |

|  |  |  |
| --- | --- | --- |
| **Age at Diagnosis** | **n** | **%** |
| <40 | 96 | 3.3% |
| 40-49 | 298 | 10.3% |
| 50-59 | 753 | 26.0% |
| 60-69 | 898 | 31.0% |
| 70-79 | 576 | 19.9% |
| 80-89 | 237 | 8.2% |
| >90 | 37 | 1.3% |

|  |  |  |
| --- | --- | --- |
| **Co-morbidities** | **n** | **%** |
| Hypertension | 1169 | 40.4% |
| Heart\_disease | 178 | 6.1% |
| Chronic\_resp\_disease | 588 | 20.3% |
| Chronic\_liver\_disease | 134 | 4.6% |
| Chronic\_kidney\_disease | 118 | 4.1% |
| Diabetes\_mellitus | 266 | 9.2% |
| Atrial\_fibrillation | 155 | 5.4% |
| NonHNCCancerDx | 275 | 9.5% |

|  |  |  |
| --- | --- | --- |
| **Year of Diagnosis** | **n** | **%** |
| Pre-2010 | 40 | 1.4% |
| 2010 | 166 | 5.7% |
| 2011 | 205 | 7.1% |
| 2012 | 214 | 7.4% |
| 2013 | 201 | 6.9% |
| 2014 | 207 | 7.2% |
| 2015 | 215 | 7.4% |
| 2016 | 216 | 7.5% |
| 2017 | 214 | 7.4% |
| 2018 | 233 | 8.0% |
| 2019 | 222 | 7.7% |
| 2020 | 177 | 6.1% |
| 2021 | 227 | 7.8% |
| 2022 | 235 | 8.1% |
| 2023 (to 4th Oct) | 123 | 4.2% |

|  |  |  |
| --- | --- | --- |
| **HN Tumour Site** | **n** | **%** |
| CUP | 99 | 3.4% |
| Hypopharynx | 152 | 5.3% |
| Lacrimal gland | 2 | 0.1% |
| Larynx | 568 | 19.6% |
| Multiple | 64 | 2.2% |
| Nasopharynx | 114 | 3.9% |
| Oral cavity | 641 | 22.1% |
| Oropharynx | 965 | 33.3% |
| Paranasal sinus/nasal cavity | 128 | 4.4% |
| Salivary gland | 162 | 5.6% |

|  |  |  |
| --- | --- | --- |
| **Status as of 4.10.23** | **n** | **%** |
| Alive | 1456 | 50.3% |
| Dead | 1439 | 49.7% |

|  |  |  |
| --- | --- | --- |
| **Histopathology** | **n** | **%** |
| Acinar cell adenocarcinoma | 11 | 0.4% |
| Adenocarcinoma | 45 | 1.6% |
| Adenoid cystic carcinoma | 58 | 2.0% |
| Adenosquamous | 3 | 0.1% |
| Ameloblastic | 6 | 0.2% |
| Basal cell adenocarcinoma | 1 | 0.0% |
| Basaloid SCC | 3 | 0.1% |
| Carcinoma ex pleomorphic adenoma | 20 | 0.7% |
| Carcinoma NOS | 10 | 0.3% |
| Carcinosarcoma | 4 | 0.1% |
| Chondrosarcoma | 1 | 0.0% |
| In situ and dysplasia | 10 | 0.3% |
| Lymphoepithelial | 2 | 0.1% |
| Melanoma | 3 | 0.1% |
| Merkel cell | 2 | 0.1% |
| Mucoepidermoid | 28 | 1.0% |
| Multiple - adenosquamous and SCC | 1 | 0.0% |
| Multiple - merkel and SCC | 1 | 0.0% |
| Multiple - SCC (sarcomatoid) and olfactory neuroblastoma | 1 | 0.0% |
| Myoepithelial | 7 | 0.2% |
| Neuroendocrine | 7 | 0.2% |
| Non-intestinal type adenocarcinoma | 1 | 0.0% |
| NPC | 82 | 2.8% |
| Olfactory neuroblastoma | 5 | 0.2% |
| Oncocytic carcinoma | 1 | 0.0% |
| Pleomorphic adenoma | 5 | 0.2% |
| Salivary duct carcinoma | 12 | 0.4% |
| SCC | 2518 | 87.0% |
| SCC (sarcomatoid) | 6 | 0.2% |
| SCC (spindle cell) | 4 | 0.1% |
| Small cell | 8 | 0.3% |
| SNUC | 8 | 0.3% |
| Transitional cell carcinoma | 1 | 0.0% |
| Undifferentiated | 20 | 0.7% |

|  |  |  |
| --- | --- | --- |
| **Disease Stage (Clinical TNM7)** | **n** | **%** |
| 0 | 6 | 0.2% |
| Benign | 5 | 0.2% |
| I | 250 | 8.6% |
| II | 297 | 10.3% |
| III | 403 | 13.9% |
| IV (unspecified) | 174 | 6.0% |
| IVA | 1371 | 47.4% |
| IVB | 204 | 7.0% |
| IVC | 118 | 4.1% |
| Unknown | 66 | 2.3% |

|  |  |  |
| --- | --- | --- |
| **Initial Treatment Received – Summary** | **n** | **%** |
| Best supportive care | 117 | 4.0% |
| Definitive cetuximab + radiotherapy | 50 | 1.7% |
| Definitive chemoradiotherapy | 441 | 15.2% |
| Treatment or referred elsewhere | 43 | 1.5% |
| Definitive radiotherapy | 497 | 17.2% |
| Died before starting palliative treatment | 4 | 0.1% |
| Induction chemotherapy + cetuximab + radiotherapy | 6 | 0.2% |
| Induction chemotherapy + chemoradiotherapy | 360 | 12.4% |
| Induction chemotherapy + definitive radiotherapy | 26 | 0.9% |
| Induction chemotherapy + palliative radiotherapy | 12 | 0.4% |
| Induction chemotherapy + surgery | 1 | 0.0% |
| Induction chemotherapy + surgery + post-operative radiotherapy | 4 | 0.1% |
| Induction chemotherapy then Cyberknife | 1 | 0.0% |
| Induction chemotherapy then died | 6 | 0.2% |
| Palliative radiotherapy | 435 | 15.0% |
| Palliative SACT | 61 | 2.1% |
| Surgery alone | 160 | 5.5% |
| Surgery + post-operative chemoradiotherapy | 169 | 5.8% |
| Surgery + post-operative radiotherapy | 497 | 17.2% |
| Surveillance | 5 | 0.2% |

|  |  |  |
| --- | --- | --- |
| **HPV Status for oropharynx ca** | **n** | **%** |
| Negative | 207 | 21.5% |
| Positive | 597 | 62.0% |
| Unknown | 159 | 16.5% |

|  |  |  |
| --- | --- | --- |
| **Induction chemo** | **n** | **%** |
| No | 2468 | 85.3% |
| Yes | 424 | 14.6% |
| Elsewhere | 3 | 0.1% |

|  |  |  |
| --- | --- | --- |
| **Concomitant chemo** | **n** | **%** |
| No | 1842 | 63.6% |
| Yes | 1029 | 35.5% |
| Elsewhere | 24 | 0.8% |

|  |  |  |
| --- | --- | --- |
| **Initial concomitant drug** | **n** | **%** |
| CARBOPLATIN | 169 | 16.0% |
| CETUXIMAB | 57 | 5.4% |
| Cis/etop | 2 | 0.2% |
| CISPLATIN | 808 | 76.7% |
| Olaparib trial | 3 | 0.3% |
| Unknown | 14 | 1.3% |

|  |  |  |
| --- | --- | --- |
| **HNC RT** | **n** | **%** |
| No | 288 | 9.9% |
| Yes (at GSTT since 2010) | 2557 | 88.3% |
| Elsewhere or historic | 50 | 1.7% |

|  |  |  |
| --- | --- | --- |
| **HNC RT Course 1 Intent** | **n** | **%** |
| Radical | 2124 | 81.5% |
| Palliative | 483 | 18.5% |